Skip to Content

Aligos Therapeutics Inc Ordinary Shares ALGS

Morningstar Rating
$1.04 −0.02 (1.89%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ALGS is trading at a 51% discount.
Price
$0.97
Fair Value
$1.53
Uncertainty
Extreme
1-Star Price
$93.19
5-Star Price
$4.68
Economic Moat
Pvkdp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALGS is a good fit for your portfolio.

Trading Information

Previous Close Price
$1.06
Day Range
$0.991.08
52-Week Range
$0.541.38
Bid/Ask
$1.03 / $1.04
Market Cap
$78.70 Mil
Volume/Avg
347,862 / 423,494

Key Statistics

Price/Earnings (Normalized)
Price/Sales
4.39
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
66

Valuation

Metric
ALGS
Price/Earnings (Normalized)
Price/Book Value
0.86
Price/Sales
4.39
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ALGS
Quick Ratio
5.68
Current Ratio
5.90
Interest Coverage
Quick Ratio
ALGS

Profitability

Metric
ALGS
Return on Assets (Normalized)
−61.60%
Return on Equity (Normalized)
−93.03%
Return on Invested Capital (Normalized)
−82.11%
Return on Assets
ALGS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRYclvbqzxRgnd$557.3 Bil
VRTX
Vertex Pharmaceuticals IncYbshnvkTfvnxj$104.5 Bil
REGN
Regeneron Pharmaceuticals IncPqwrqwdfLcfkzz$103.6 Bil
MRNA
Moderna IncGhdpylbdpZrqx$42.7 Bil
ARGX
argenx SE ADRXjfkgdpkFltb$22.8 Bil
BNTX
BioNTech SE ADRDsnhsmfghSyw$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncQkynhvqxsFnykm$19.7 Bil
BMRN
Biomarin Pharmaceutical IncGyhwmhyJftjyvr$16.9 Bil
RPRX
Royalty Pharma PLC Class AGjrkjylnyXpjhfjx$13.3 Bil
INCY
Incyte CorpJfmcwkdmNdwbm$12.4 Bil

Sponsor Center